Central Precocious Puberty

6
Pipeline Programs
3
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
4
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
3 programs
2
LeuprorelinPhase 41 trial
Leuprorelin Acetate Depot 3MPhase 41 trial
EnantoneN/A1 trial
Active Trials
NCT02993926Completed108Est. Sep 2018
NCT02427958Completed307Est. Nov 2018
NCT05341115Completed80Est. Mar 2025
Debiopharm
DebiopharmSwitzerland - Lausanne
2 programs
2
Debio 4326Phase 31 trial
TriptorelinPhase 31 trial
Active Trials
NCT06129539Active Not RecruitingEst. Feb 2028
NCT01467882CompletedEst. Jul 2014
Ipsen
IpsenChina - Tianjin
2 programs
2
Triptorelin PamoatePhase 31 trial
Triptorelin pamoate 15mgPhase 31 trial
Active Trials
NCT05029622Completed66Est. Feb 2023
NCT04736602Completed32Est. Sep 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
TakedaLeuprorelin Acetate Depot 3M
TakedaLeuprorelin
DebiopharmDebio 4326
IpsenTriptorelin Pamoate
IpsenTriptorelin pamoate 15mg
DebiopharmTriptorelin
TakedaEnantone

Clinical Trials (7)

Total enrollment: 593 patients across 7 trials

NCT05341115TakedaLeuprorelin Acetate Depot 3M

A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty

Start: Mar 2023Est. completion: Mar 202580 patients
Phase 4Completed
NCT02427958TakedaLeuprorelin

A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants

Start: Aug 2015Est. completion: Nov 2018307 patients
Phase 4Completed
NCT06129539DebiopharmDebio 4326

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)

Start: Jul 2024Est. completion: Feb 2028
Phase 3Active Not Recruiting
NCT05029622IpsenTriptorelin Pamoate

A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.

Start: Aug 2021Est. completion: Feb 202366 patients
Phase 3Completed
NCT04736602IpsenTriptorelin pamoate 15mg

Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.

Start: Mar 2021Est. completion: Sep 202232 patients
Phase 3Completed
NCT01467882DebiopharmTriptorelin

Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty

Start: Apr 2012Est. completion: Jul 2014
Phase 3Completed
NCT02993926TakedaEnantone

A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants

Start: Jun 2017Est. completion: Sep 2018108 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space